Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL13584261 | 0.99 | GAA (0.43) | GAAKMT2AMEN1CA12CA1 | |
| SCHEMBL11816021 | 0.82 | MEN1 (0.44) | KMT2AMEN1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1171548 | 0.80 | CNR2 (0.45) | GAAKMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL13584151 | 0.78 | CA12 (0.46) | GAAKMT2AMEN1CA12CA1 | |
| Hydrochloric Acid SCHEMBL13584664 | 0.77 | CA12 (0.45) | GAAKMT2AMEN1CA12CA1 | |
| SCHEMBL14868756 | 0.77 | TSHR (0.53) | GAAKMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL1170158 | 0.76 | CNR2 (0.44) | GAAKMT2AMEN1NPSR1LMNA | |
| SCHEMBL5200019 | 0.75 | LMNA (0.40) | KMT2AMEN1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL13584269 | 0.74 | MEN1 (0.45) | GAAKMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL13521679 | 0.74 | SMN1; SMN2 (0.39) | GAAKMT2AMEN1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180256520-A1 | BIGUANIDE DERIVATIVE, A PREPARATION METHOD THEREOF, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE INGREDIENT | HANALL BIOPHARMA CO., LTD. (KR) | 2018-09-13 | — | — | US | claimed |
| US-9993446-B2 | Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2018-06-12 | — | — | US | claimed |
| US-20160317478-A1 | Biguanide Derivative, A Preparation Method Thereof, And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | IMMUNOMET THERAPEUTICS INC. | 2016-11-03 | — | — | US | claimed |
| US-9416098-B2 | Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2016-08-16 | — | — | US | claimed |
| EP-2522653-A2 | BIGUANIDE DERIVATIVE, A PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE INGREDIENT | HanAll Biopharma Co., Ltd. (KR) | 2012-11-14 | — | — | EP | claimed |
| US-20120283299-A1 | Biguanide Derivative, A Preparation Method Thereof And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | HANALL BIOPHARMA CO., LTD. (KR) | 2012-11-08 | — | — | US | claimed |
| US-10376480-B2 | Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10376480-B2 | Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180256520-A1 | BIGUANIDE DERIVATIVE, A PREPARATION METHOD THEREOF, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE INGREDIENT | HANALL BIOPHARMA CO., LTD. (KR) | 2018-09-13 | — | — | US | disclosed |
| US-9993446-B2 | Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9993446-B2 | Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9993446-B2 | Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20160317478-A1 | Biguanide Derivative, A Preparation Method Thereof, And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | IMMUNOMET THERAPEUTICS INC. | 2016-11-03 | — | — | US | disclosed |
| US-9416098-B2 | Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416098-B2 | Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416098-B2 | Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient | IMMUNOMET THERAPEUTICS INC. (US) | 2016-08-16 | — | — | US | disclosed |
| EP-2522653-A2 | BIGUANIDE DERIVATIVE, A PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE INGREDIENT | HanAll Biopharma Co., Ltd. (KR) | 2012-11-14 | — | — | EP | disclosed |
| US-20120283299-A1 | Biguanide Derivative, A Preparation Method Thereof And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | HANALL BIOPHARMA CO., LTD. (KR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283299-A1 | Biguanide Derivative, A Preparation Method Thereof And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | HANALL BIOPHARMA CO., LTD. (KR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283299-A1 | Biguanide Derivative, A Preparation Method Thereof And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | HANALL BIOPHARMA CO., LTD. (KR) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180256520-A1 | BIGUANIDE DERIVATIVE, A PREPARATION METHOD THEREOF, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE INGREDIENT | PRKAG1, PRKAG3, PRKAG2 | GAA 746/4885KMT2A 2501/4885MEN1 109/4885 |
| US-20120283299-A1 | Biguanide Derivative, A Preparation Method Thereof And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | PRKAG1, PRKAG2, PRKAG3 | GAA 815/4885KMT2A 2514/4885MEN1 82/4885 |
| US-20160317478-A1 | Biguanide Derivative, A Preparation Method Thereof, And A Pharmaceutical Composition Containing The Biguanide Derivative As An Active Ingredient | PRKAG1, PRKAG3, PRKAG2 | GAA 794/4885KMT2A 2430/4885MEN1 98/4885 |
| US-10376480-B2 | Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient | PRKAG1, PRKAG3, PRKAG2 | GAA 746/4885KMT2A 2501/4885MEN1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.